Physician profile
Wei Ye
NPI 1962678458
$3,050.37
in general payments reported to CMS, 2019-2025
18 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $103 · 2021: $153 · 2022: $600 · 2023: $401 · 2024: $592 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $698.60 | 2019-2024 | |
| Amarin Pharma, INC. | $544.67 | 2019-2022 | |
| Amgen INC. | $411.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $259.16 | 2022-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $205.71 | 2021-2025 | Ubrelvy, Qulipta |
| Axsome Therapeutics, INC. | $137.50 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $125.00 | 2024 | Xarelto |
| Lilly USA, LLC | $120.28 | 2019-2023 | Mounjaro |
| Boston Scientific Corporation | $116.38 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $109.46 | 2024-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $86.61 | 2023-2024 | Arexvy, Shingrix |
| Progenics Pharmaceuticals, INC. | $46.33 | 2024 | |
| Merck Sharp & Dohme LLC | $41.81 | 2022 | |
| Pfizer INC. | $41.74 | 2023 | |
| Ibsa Pharma INC. | $41.26 | 2023 | Tirosint, Licart |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $24.84 | 2024 | Voquezna |
| Agios Pharmaceuticals, INC. | $24.01 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.